Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rFIX · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| rFIX | DRUG | - |
| rFIX-R | DRUG | - |
Inclusion Criteria: * Hemophilia B (FIX:C less than 2%) * Previous treatment of at least 150 exposure days using any FIX product * 12 years of age and older Exclusion Criteria: * The patient has a currently detectable factor IX inhibitor or a history of inhibitors. (A family history of inhibitors...
Top 8 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 15 | PHASE3 | Concizumab, Mim8, Denecimig, NNC0442-0344 A, turoctocog alfa pegol |
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Fitusiran, efanesoctocog alfa |
| Pfizer Inc. | PFE | 8 | PHASE3 | Fidanacogene elaparvovec, Marstacimab |
| BioMarin Pharmaceutical Inc. | BMRN | 2 | PHASE3 | Valoctocogene roxaparvovec |
| Hoffmann-La Roche | RHHBY | 8 | PHASE3 | Emicizumab, NXT007, SPK-8011QQ, SPK-8011, SPK-8016 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | REGV131, LNP1265 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE1 | AskBio009 |
| Bayer | BAYRY | 6 | - | Damoctocog-alfa-pegol |
rFIX is a recombinant factor IX therapy used for the treatment of Hemophilia B, a bleeding disorder caused by a deficiency of clotting factor IX. It is being developed by Pfizer, Inc. and is currently in Phase 3 clinical development, meaning it is investigational and not yet approved.
rFIX is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical trials for the treatment of Hemophilia B.
rFIX is in Phase 3 clinical development for the treatment of Hemophilia B. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, with a total enrollment of 23 participants in one of the studies.
rFIX has been studied in two completed Phase 3 clinical trials. The first, NCT00093171, evaluated rFIX (BeneFIX) in Hemophilia B with 23 participants aged 12 years and older in the United States. The second, NCT00093210, evaluated recombinant human factor IX (BeneFIX) and a new formulation (rFIX-R) in moderate to severe Hemophilia B.
Yes, rFIX is also known as BeneFIX. The clinical trials NCT00093171 and NCT00093210 refer to rFIX as BeneFIX, and the second trial also evaluates a new formulation called rFIX-R. Both are recombinant factor IX products for Hemophilia B.